Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMURAI: Tocilizumab Monotherapy in RA
NCT00144508Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2003
- Primary completion
- May 2004
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 3, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change in the erosion score, as determined by the modified Sharp method at 52 weeks. Started Mar 2003; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00144508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144508.